Fortress Biotech’s latest 10-Q filing reveals near-term financing limitations due to paused Series A Preferred Stock dividends, restricting access to its primary equity shelf. Nonetheless, Fortress maintains a robust cash position and diversified capital strategies via subsidiaries such as Journey Medical’s sizeable shelf registration and ATM sales programs. The holding company’s multi-subsidiary structure provides operational flexibility and strategic depth across distinct therapeutic areas, balancing clinical development risk with multiple growth vectors. Key risks include regulatory approval uncertainty and compliance with tightening loan covenants amid this complex operating model.